News & Information
Jesse's Story
Jesse Penn's story highlights the importance of prostate cancer survivors knowing about their bone health.
Jesse Penn's story highlights the importance of prostate cancer survivors knowing about their bone health.
FDA approves Bayer’s Nubeqa®, a new treatment for men with non-metastatic castration-resistant prostate cancer
Nubeqa was approved under the FDA’s Priority Review designation; approval granted three months ahead of target FDA action date.
Nubeqa was approved under the FDA’s Priority Review designation; approval granted three months ahead of target FDA action date.
Clinical Trials: Another Treatment Option for Patients - Thomas Farrington Interview with URO TodayPHEN President Tom Farrington talks to Dr. Alicia Morgans, Assoc. Professor of Medicine at the Northwestern University Feinberg School of Medicine on how to engage best with patients.
Highly Successful Daddy's Boys Stage Play in New Orleans, LA
PHEN presented the “Daddy’s Boys" stage play on June 29th at the Southern University of New Orleans.
PHEN presented the “Daddy’s Boys" stage play on June 29th at the Southern University of New Orleans.
New BRCA Blue campaign educates about the link between BRCA gene mutations and cancer
Prostate Conditions Education Council in partnership with other leading prostate cancer advocacy organizations, announces the launch of the BRCA Blue Campaign.
Prostate Conditions Education Council in partnership with other leading prostate cancer advocacy organizations, announces the launch of the BRCA Blue Campaign.
Prostate Cancer ADT Raises Dementia Risk, Study Finds
Men who receive androgen deprivation therapy for prostate cancer are at increased risk for dementia, according to a new study.
.jpg)
Presenter: Keith Crawford, MD, PhD
Director of Clinical Trials and Patient Education
Prostate Health Education Network
First Baptist Church of Highland Park
6801 Sheriff Rd., Landover, MD 29785